Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical review

Testosterone Review Links Levels to Atrial Fibrillation

Analysis based on 6 articles · First reported Sep 01, 2026 · Last updated Sep 10, 2026

Sentiment
0
Attention
1
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The review is unlikely to move broad markets but could influence sentiment around testosterone replacement therapy products and the pharmaceutical companies that manufacture them, as it raises questions about optimal dosing targets. Any shift toward lower target levels or steady-release formulations could modestly affect prescribing patterns and product mix in the hormone therapy market.

pharmaceuticals healthcare

A narrative review published in the Journal of the Pediatric Endocrine Society concludes that the relationship between testosterone levels and atrial fibrillation (AF) appears to follow a U-shaped pattern, with both low and high testosterone associated with higher AF risk and the lowest risk in the middle of the normal range. The review, co-authored by Rajat S. Barua of the United States — Providence Veterans Affairs Medical Center, Anand Reddy Maligireddy of the University of Kansas Medical Center, and Shumedha T. Barua of the Kansas City VA Medical Center, synthesizes population studies, clinical research, and laboratory work reported since 2025. The authors suggest clinicians treating men with testosterone replacement therapy aim for a total testosterone target of roughly 350-550 ng/dL rather than the high end of normal, prefer steady-release formulations for men with elevated cardiovascular or arrhythmic risk, use calculated free testosterone when sex hormone-binding globulin is abnormal, maintain normal hematocrit, and monitor heart rhythm, blood pressure, and kidney and liver function. The review received no external funding and is a narrative summary rather than a meta-analysis, so its conclusions are interpretive and the proposed target range has not been tested prospectively.

60 Pediatric Endocrine Society published review
50 Rajat S. Barua co-authored review
30 Anand Reddy Maligireddy co-authored review
30 Shumedha T. Barua co-authored review
per
Barua is the lead co-author and primary spokesperson for the review, quoted extensively on the U-shaped risk pattern and the need for individualized, monitored testosterone treatment.
Importance 70.0 Sentiment 0.0
ngo
The Pediatric Endocrine Society published the review in its Journal of the Pediatric Endocrine Society, positioning it as a source of clinical guidance on testosterone therapy safety.
Importance 60.0 Sentiment 0.0
govactor
The center is the affiliation of lead co-author Rajat S. Barua and co-author Shumedha T. Barua, lending institutional credibility to the review.
Importance 40.0 Sentiment 0.0
per
Maligireddy is a co-author of the review from the University of Kansas Medical Center.
Importance 20.0 Sentiment 0.0
per
Shumedha T. Barua is a co-author of the review from the Kansas City VA Medical Center.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.